Vaccines Available in November, How Much Corona Vaccines Are Needed in Indonesia? All pages

KOMPAS.com – The Indonesian government will begin accepting vaccine shipments in November 2020.

Various preparations have been made, including the selection of health facilities to administer the vaccine that month.

The Director General of Disease Prevention and Control of the Ministry of Health of the Republic of Indonesia, Dr. Achmad Yurianto, said that there are three vaccines that have been purchased by the government because they have passed phase three of clinical trials and are expected to are administered to the Indonesian people.

The three vaccines in question are the Sinovac, Sinopharm and Cansino vaccines, which have also been tested in several countries.

Also read: Corona vaccine will be available soon, epidemiologist calls dangerous emergency use authorization

With the total population of Indonesia based on data from the Ministry of the Interior through the General Directorate of Population and Civil Registration (Dukcapil) 2020 reaching 268,583,016 people, will all Indonesian residents be vaccinated?

Yuri mentioned in the response to the Covid-19 pandemic, if you want to achieve community immunity or Herd immunity, then it is not necessary to vaccinate 100 percent of people.

“Enough in the 70 percent range, we can actually achieve this Herd immunity or immunity immunity, “Yuri said in press conference: Update on the preparation for the Covid-19 vaccine in Indonesia, Monday (10/19/2020).

“Well, this base is the one we use later, our calculations only reach Herd immunity, that is, around 160 million people (who need to be vaccinated), “he continued.

Yuri continued, if the vaccine was later administered using the platform used by Sinovac, which was to be produced by Biofarma, two boxes would be needed.

In other words, the vaccine requirement is roughly double 160 million, which is 320 million vaccines.

Not only that, the calculation of the administration of the vaccine must also consider the age group and the requirements that have been used in the implementation of the phase 3 clinical trials.

For the Sinovac and Cansino vaccine products, these two vaccines are only applied in the age group 18 to 59 years.

“So, this is the group against which we are going to vaccinate, and the clinical trial is also mentioned, in that group there should be no serious comorbidity,” he explained.

Also read: There is still no powerful vaccine against Covid-19, why do vaccines start in November?

SHUTTERSTOCK / Orpheus FX Corona Vaccine Illustration, The Oxford, England vaccine trial resumed after a week that was stopped because one of the volunteers was ill.

So what about people outside of the 18 to 59 age group?

On this issue, Yuri said that so far his party did not have data from clinical trials, related to the provision of vaccines outside the age group of 18 to 59 years.

“No clinical trials have been conducted in ages 0 to 18 (years), no clinical trials have been conducted in ages over 60 years”,

“So, we will not vaccinate the group outside the 18-59 years,” he added.

However, he emphasized, this does not mean that the age group outside the 18-59 age group will be ignored.

Because, over time, related parties will also carry out more research related to the provision of the Covid-19 vaccine at an age outside of existing clinical trial data.

“This is what we must understand together, it does not mean that we leave,” Yuri said.

Also Read: While Waiting for the Covid-19 Vaccine, Why Do Adults Need Flu and PCV Vaccines?

“And not all ages 18 to 59 will receive the Covid-19 vaccine, because in the group that has severe comorbidities, there is not yet a clinical trial,” he added.

Yuri added that if it was seen by their availability, the vaccines could not be directly administered to 320 million people simultaneously.

The government will provide the vaccine based on availability and in order, as well as the susceptibility group to exposure to Covid-19.

For vaccine availability in November-December 2020, Yuri mentioned, only about 9.1 million.

Also Read: 3 Chinese Corona Vaccines Are Named That Have Passed Phase Three Clinical Trials, Expert Says